Abstract
As part of the innate immune system, natural killer (NK) cells are regarded as promising effector cells for adoptive cell therapy approaches to treat patients with cancer. In some cases, genetic modification of the NK cells may be considered but such manipulation has to be integrated into the expansion method to allow the generation of clinically relevant numbers of gene-modified NK cells. Therefore, an efficient gene transfer procedure is needed.
Our group developed a retrovirus-based transduction protocol capable of robust expansion of gene-modified NK cells with a high rate of transgene expression. Actively dividing cells is a prerequisite for efficient gene transfer when using a retroviral vector. In the procedure presented here, strong activation of the NK cells was provided by a combination of IL-15 and the K-562 feeder cells. Beside the interest in developing a simple procedure compliant with good manufacturing practice (GMP) for the production of therapeutic products, this approach also provides a valuable means of generating genetically modified primary NK cells for future preclinical studies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Caligiuri MA (2008) Human natural killer cells. Blood. doi:10.1182/blood-2007-09-077438
Bryceson YT, March ME, Ljunggren HG et al (2006) Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. doi:10.1182/blood-2005-04-1351
Marcus A, Gowen BG, Thompson TW et al (2014) Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol. doi:10.1016/B978-0-12-800267-4.00003-1
Brandt CS, Baratin M, Yi EC et al (2009) The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med. doi:10.1084/jem.20090681
Baychelier F, Sennepin A, Ermonval M et al (2013) Identification of a cellular ligand for the natural cytotoxicity receptor NKp44. Blood. doi:10.1182/blood-2013-03-489054
Miller JS, Soignier Y, Panoskaltsis-Mortari A et al (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. doi:10.1182/blood-2004-07-2974
Geller MA, Cooley S, Judson PL et al (2011) A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. doi:10.3109/14653249.2010.515582
Parkhurst MR, Riley JP, Dudley ME et al (2011) Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res. doi:10.1159/1078-0432.CCR-11-1347
Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive cells in the tumor microenvironment. Nat Immunol. doi:10.1038/ni.2703
Bollard CM, Rossig C, Calonge MJ et al (2002) Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood. doi:10.1182/blood.V99.9.3179
Carlsten M, Childs RW (2015) Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications. Front Immunol. doi:10.3389/fimmu.2015.00266
Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G et al (2000) Gene Therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. doi:10.1126/science.288.5466.669
Pule MA, Savoldo B, Myers GD et al (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. doi:10.1038/nm.1882
Pillet AH, Bugault F, Theze F et al (2009) A programmed switch from IL-15- to IL-2-dependent activation in human NK cells. J Immunol. doi:10.4049/jimmunol.0801933
Yvon E, Del Vecchio M, Savoldo B et al (2009) Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res. doi:10.1158/1078-0432.CCR-08-3163
Denman CJ, Senyukov VV, Somanchi SS et al (2012) Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One. doi:10.1371/journal.pone.0030264
Acknowledgment
This work was supported by the Department of Defense grant CA140114 (E.Y., C.R.C., and C.M.B.) and The University of Texas MD Anderson Cancer Center Internal Research Grant (E.Y.).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Kellner, J.N., Cruz, C.R., Bollard, C.M., Yvon, E.S. (2016). Gene Modification of Human Natural Killer Cells Using a Retroviral Vector. In: Somanchi, S. (eds) Natural Killer Cells. Methods in Molecular Biology, vol 1441. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3684-7_17
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3684-7_17
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3682-3
Online ISBN: 978-1-4939-3684-7
eBook Packages: Springer Protocols